@article{oai:showa.repo.nii.ac.jp:00003361,
 author = {NOMURA, Norihiro and ITO, Takayoshi and SHINOHARA, Hiroki and SHIMA, Nobukazu and SATOU, Masashi and SAKUMA, Dai and EGUCHI, Junichi and URAGAMI, Naoyuki and DEGUCHI, Yoshio and YOKOYAMA, Noboru and INOUE, Haruhiro},
 issue = {4},
 journal = {The Showa University journal of medical sciences},
 month = {2019-12, 2020-06-02},
 note = {Hepatocellular carcinoma（HCC）is the sixth most commonly diagnosed cancer worldwide. Sorafenib is an oral multikinase inhibitor used in the palliative treatment of advanced HCC. However, there were no reported cases of complete response（CR）from two previous large phaseⅢ clinical trials. Here, we report a case of CR in a patient with advanced HCC with multiple lymph node and bone metastases, treated with sorafenib monotherapy for 8 months. To our knowledge, this is the first evidence showing CR following sorafenib monotherapy for HCC with bone metastasis.},
 pages = {373--378},
 title = {Complete Response Using Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma with Multiple Lymph Node and Bone Metastases: A Case Report},
 volume = {31},
 year = {}
}